Skip to content
    Compare notes on r/BodyHackGuideCompare notes with other researchers. Join r/BodyHackGuide
    Growth Hormone / IGF-1 AxisPhase II

    Hexarelin Dosage Guide: Protocols, Calculator & Safety

    Everything you need to know about Hexarelin dosing: protocols and safety.

    Dose Range

    100–200 mcg per injection

    Frequency

    1–2 times daily; subject to desensitization within 4 weeks

    Cycle Length

    4-6 weeks (desensitization limits longer use)

    Half-Life

    ~55 minutes is often quoted, but in Imbimbo 1994 (PMID 7957536) that is the half-life of the growth hormone rise after an IV dose, not of hexarelin itself; hexarelin's own elimination half-life after an IV dose was about 76 minutes in rats (PMID 10611139)

    Administration Routes

    SubcutaneousIntramuscular

    Quick Reconstitution Calculator

    Calculate syringe units instantly

    Syringe Draw

    10.0 units

    2500 mcg/ml · 0.100 ml draw

    Full Tool

    For laboratory research use only. This tool performs reconstitution math (concentration and syringe-unit conversion) and is not dosing guidance for humans or animals.

    Dosing Protocols

    Beginner

    Conservative beginner protocol:

    • Dose: 100 mcg subcutaneous per injection
    • Frequency: 1-2x daily
    • Timing: Fasted — pre-breakfast and/or pre-bed
    • Duration: 4-6 weeks on, then 2-4 weeks off before restarting
    • Never continuous use without cycling

    Reconstitution: 5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL. A 100 mcg dose = 0.04 mL = 4 units on U-100 insulin syringe.

    Why short cycles: Twice-daily hexarelin partly blunted the GH response by week 4 in 12 healthy older adults, and a 4-week break restored it (PMID 10990150); no study has compared this with GHRP-2 or GHRP-6. Keeping cycles to 4-6 weeks, with breaks between them, is meant to let the response recover and limit cumulative HPA exposure.

    Timing options:

    • Simplest: 100 mcg pre-bed only (single daily injection, aligns with nocturnal GH pulse)
    • Standard: 100 mcg pre-breakfast + 100 mcg pre-bed (two-dose protocol)
    • Intensive (not recommended for beginners): 100 mcg pre-breakfast + pre-training + pre-bed (three-dose protocol has higher cortisol exposure)

    Why fasted: Elevated glucose and insulin blunt GH release through increased somatostatin tone. Hexarelin is no exception — dose 2-3 hours after last meal minimum.

    Labs to run before starting:

    • IGF-1 (baseline)
    • Fasting insulin, fasting glucose, HbA1c
    • Comprehensive metabolic panel
    • AM cortisol, prolactin (hexarelin raises both, about as much as GHRP-2 at the same dose)
    • ACTH (optional; helpful if HPA axis concerns)

    Recheck at week 4 and week 6 (end of cycle).

    Who should not use hexarelin:

    • Users with anxiety, mood disorders, or HPA dysregulation
    • Users with prolactin-sensitive conditions
    • Users seeking continuous long-term GH support (choose ipamorelin instead)
    • Users in caloric deficit (the appetite and cortisol effects interfere)
    Standard

    Optimized intermediate protocol:

    • Dose: 150-200 mcg SC per injection
    • Frequency: 2x daily (pre-breakfast + pre-bed)
    • Cycle: 4-6 weeks on / 2-4 weeks off
    • Stack: Paired with GHRH analog for synergistic effect

    Hexarelin + GHRH stack:

    • Hexarelin: 150-200 mcg SC
    • Sermorelin: 200-300 mcg SC, OR
    • CJC-1295 (no-DAC): 100-150 mcg SC, OR
    • Tesamorelin: 1 mg SC (if VAT reduction is also desired)
    • Drawn into same insulin syringe, injected together

    The hexarelin tradeoff: Combined hexarelin+GHRH released more GH than either peptide alone in healthy adults (PMIDs 8799695 and 10754475). Hexarelin also raises cortisol and prolactin (PMID 7586608), about as much as GHRP-2 at the same dose (PMID 10195374). Use this stack when maximum GH pulse is needed for a short (4-6 week) intensive phase, then transition to ipamorelin+CJC for maintenance.

    Short-phase strategy (common use pattern):

    Week 1-4: Intensive hexarelin + GHRH phase for peak GH pulses Week 5-8: Washout (no GHS) or transition to low-dose ipamorelin Week 9-12: Maintenance with ipamorelin + CJC no-DAC if continued GH support desired Repeat intensive cycle after 8+ weeks off hexarelin

    Monitoring during cycle:

    • Week 2: Fasting glucose (hexarelin's insulin sensitivity effects appear fastest)
    • Week 4: IGF-1, cortisol, prolactin (end-of-cycle benchmark)
    • Week 6 (if extended): IGF-1, fasting glucose

    If cortisol has risen significantly above baseline at week 4, shorten the cycle or reduce dose.

    Dose ceiling: 200 mcg per injection is the practical upper limit. Beyond this, GHS-R1a receptor saturation prevents additional GH release while cortisol continues to rise proportionally.

    Advanced

    Advanced strategic use — hexarelin as a specific tool:

    Experienced peptide users often position hexarelin as a situational compound rather than a continuous-use GHS. Appropriate contexts:

    Short anabolic intensification phase (4-6 weeks):

    • Hexarelin 200 mcg SC + CJC-1295 no-DAC 150 mcg SC, 2x daily (fasted)
    • Combined with:
      • Testosterone replacement (if applicable)
      • BPC-157 500 mcg BID for connective tissue support
      • TB-500 2-2.5 mg twice weekly for soft tissue remodeling
      • Disciplined progressive overload training
      • Caloric surplus with high protein (1g/lb bodyweight)

    After 4-6 weeks, transition to ipamorelin + CJC for 8+ weeks before considering another hexarelin cycle.

    Cardiac research context:

    The CD36-mediated cardioprotective effects have motivated research interest in hexarelin for cardiac applications. Any such use should be under formal clinical research protocols or specialist medical supervision — it is not appropriate for self-experimentation.

    Situations where hexarelin is the wrong choice:

    • Continuous daily long-term GH optimization — the partial blunting of hexarelin's GH response with repeated twice-daily use (PMID 9589671) and its cortisol and prolactin rises (PMID 7586608) make ipamorelin a better fit, although no published human study of ipamorelin has lasted longer than 7 days (PMID 25331030)
    • Caloric deficit / cutting phases — appetite and cortisol effects interfere with deficit maintenance
    • Users with anxiety, HPA dysregulation, or prolactin sensitivity — use ipamorelin instead
    • Users with established cardiovascular disease — while preclinical CD36 data is favorable, no clinical cardiac indication has been validated; the acute blood pressure and cortisol effects may be problematic
    • Users on GLP-1 agonists during active deficit — opposing appetite signals

    Combinations to manage:

    • Hexarelin + testosterone replacement: Additive anabolic effects; standard for short aggressive phases
    • Hexarelin + BPC-157/TB-500: Complementary; different pathways; safe stacking
    • Hexarelin + NAD+ or longevity protocols: Non-interfering but hexarelin's cortisol profile makes it a poor fit for longevity-focused protocols that emphasize HPA axis moderation

    Combinations to avoid:

    • Hexarelin + other GHRPs (GHRP-2, GHRP-6, ipamorelin, MK-677) — mechanistically redundant
    • Hexarelin + glucocorticoid therapy — additive HPA load, reduced GH response
    • Hexarelin + aggressive stimulants — additive HPA and sympathomimetic load

    Discontinuation triggers:

    • Cortisol/prolactin elevation beyond acceptable thresholds on lab follow-up
    • Mood changes, new anxiety, or insomnia
    • Fasting glucose >110 mg/dL persistently
    • Persistent joint pain or edema
    • Any cardiovascular symptoms
    • Body composition changes suggesting cumulative cortisol effects (central adiposity, buffalo hump, moon face)

    Weight-Based Dosing

    1–2 mcg/kg per injection.

    Commonly Stacked With

    Synergistic Combinations

    Hexarelin + GHRH analog (sermorelin, CJC-1295 no-DAC, or tesamorelin): Given with GHRH in a single intravenous test, hexarelin released more GH than either peptide alone, and the interaction was synergistic in healthy men (Giustina et al., 1996). Reserved for short (4-6 week) intensive phases.

    Hexarelin + BPC-157 + TB-500: Standard peptide-enhanced recovery stack for aggressive training intensification. Hexarelin drives systemic anabolism; BPC-157 supports connective tissue; TB-500 accelerates soft tissue remodeling. Non-interfering mechanisms.

    Hexarelin + Testosterone replacement (in hypogonadal men): Additive anabolic effects during short anabolic phases. Standard when both axes are clinically indicated.

    Situational

    Hexarelin + Carnosine / beta-alanine: No direct interaction; used together in performance-focused programs. Carnosine for muscle buffering, hexarelin for GH pulse.

    Hexarelin + Creatine: No interaction. Complementary for short-duration power and hypertrophy goals.

    Redundant (Avoid)

    Hexarelin + GHRP-2, GHRP-6, or Ipamorelin: All GHS-R1a agonists — mechanistically redundant. If you want hexarelin's potency, dose it alone. If you want less HPA effect, switch to ipamorelin rather than layering.

    Hexarelin + MK-677: Both GHS-R1a agonists. MK-677 provides 24-hour receptor occupancy; adding short-pulse hexarelin produces diminishing returns and stacks the cortisol effects.

    Avoid or Contraindicated

    Hexarelin + Glucocorticoids (prednisone, dexamethasone): Additive HPA axis load; pharmacodynamic interference with GH response.

    Hexarelin + Exogenous HGH: Pharmacologically counterproductive — exogenous GH suppresses endogenous pituitary output via IGF-1 negative feedback.

    Hexarelin + High-dose stimulants (aggressive pre-workouts with yohimbine/DMHA/high caffeine): Additive sympathomimetic and HPA load, particularly problematic given hexarelin's cortisol profile.

    Hexarelin + GLP-1 agonists during active weight loss phases: Opposing appetite signals; defeats the purpose of both.

    Hexarelin + MAO inhibitors or other psychiatric drugs with cortisol-sensitive interactions: Theoretical concern; specialist oversight needed.

    Related Compound Pages

    • GHRP-2 — Similar hexapeptide; raised cortisol, ACTH and prolactin about as much as hexarelin at the same dose (PMID 10195374)
    • GHRP-6 — Similar with stronger appetite effect
    • Ipamorelin — GHS-R1a agonist that did not raise ACTH or cortisol beyond GHRH levels in swine (PMID 9849822); preferred for chronic use
    • CJC-1295 — GHRH synergy partner
    • Sermorelin — Pulsatile GHRH synergy partner
    • Tesamorelin — FDA-approved GHRH analog
    • MK-677 — Oral long-acting GHS alternative
    • BPC-157 — Tissue repair stack partner
    • TB-500 — Soft tissue remodeling stack partner
    • NAD+ — Mitochondrial longevity support

    Side Effects & Safety

    ## Common - **Facial flushing and warmth** — More pronounced than other GHRPs. Fades within 15-30 minutes. - **Injection site reactions** — Mild erythema, occasional stinging at SC site. Site rotation minimizes. - **Cortisol elevation** (significant after a 2 mcg/kg IV dose, PMID 7586608; similar with GHRP-2 at the same dose, PMID 10195374) — Transient, peaks 60-90 min post-injection, resolves by 3-4 hours. In healthy users with normal HPA function, typically clinically inconsequential per single dose; cumulative chronic exposure matters more. - **Prolactin elevation** — Usually modest; GHRP-2 at the same intravenous dose raised prolactin to a similar level in young adults ([Arvat et al., 1999](https://pubmed.ncbi.nlm.nih.gov/10195374/)), and no human study has compared hexarelin with ipamorelin. Relevant in users with prolactin-sensitive conditions. - **Appetite stimulation** — Intermediate; noticeable but less pronounced than GHRP-6. - **Vivid dreams** — Common with bedtime dosing. ## Less Common - **Headache** — More frequent than with other GHRPs, particularly in first week. - **Mild nausea** — More common with higher doses or IV administration. - **Transient hypotension** — Primarily with rapid IV bolus; SC route rarely produces meaningful BP changes. - **Fluid retention** — Mild, most pronounced in first 2-3 weeks of daily use. - **Insulin sensitivity reduction** — Measurable with chronic dosing; monitor HbA1c and fasting insulin. - **Paresthesia / scalp tingling** — Transient, benign. ## HPA Axis Effects - **ACTH elevation** — Meaningful and measurable; GHRP-2 at the same intravenous dose raised ACTH to a similar level in young adults ([Arvat et al., 1999](https://pubmed.ncbi.nlm.nih.gov/10195374/)) - **Cumulative cortisol exposure** with chronic daily dosing could theoretically contribute to HPA dysregulation over months - **Patients with anxiety, cortisol-sensitive mood disorders, or adrenal insufficiency are poor candidates** for hexarelin ## Receptor Desensitization - **GH response attenuation** within 4-8 weeks of continuous daily dosing - Dose escalation to overcome attenuation increases cortisol and prolactin exposure disproportionately - Shorter cycling (4-6 weeks on / 2-4 weeks off) is standard for this compound specifically ## Rare but Notable - **Significant hypotension** — primarily with IV; rare with SC - **Hypersensitivity reactions** — rare local or systemic - **Persistent insulin resistance** — with prolonged high-dose use - **HPA axis blunting** — theoretical concern with long-term continuous dosing ## Long-term Theoretical Concerns As with all GH-axis interventions, sustained IGF-1 elevation raises theoretical concerns around chronic mitogenic signaling and cancer risk. Hexarelin's HPA axis effects add an additional concern — chronic low-grade cortisol elevation has independent metabolic consequences (visceral fat accumulation, insulin resistance, immune suppression) that compound over long timescales. Short-cycle use minimizes this risk significantly. ## Signs You Are Overdosing or Need to Stop - Persistent joint pain, peripheral edema, or carpal tunnel symptoms (IGF-1 too high) - Fasting glucose persistently >110 mg/dL - Mood changes, insomnia, or anxiety (HPA axis effects) - Central weight gain or Cushing-like body composition changes - Persistent elevated resting heart rate - Worsening sleep apnea - Any cardiovascular symptoms

    Contraindications

    Hexarelin is contraindicated or requires strict caution in: - **Active malignancy** — particularly hormone-responsive cancers; IGF-1 elevation theoretical risk - **Strong family history of GH-axis sensitive cancers** — specialist supervision required - **Pregnancy and lactation** — no established safety data - **Known hypersensitivity** to hexarelin or related hexapeptides - **Severe untreated obstructive sleep apnea** — stabilize with CPAP first - **Acute critical illness** — GH-axis stimulation inappropriate during sepsis, post-surgical recovery, multiple trauma, respiratory failure - **Diabetic ketoacidosis or severe uncontrolled diabetes** — resolve metabolic state first - **Active proliferative retinopathy** — relative contraindication - **Hypothalamic-pituitary disease with untreated adrenal insufficiency** — hexarelin's HPA effects may be unreliable in this context - **Active Cushing's syndrome or elevated baseline cortisol** — hexarelin adds meaningfully to HPA load - **Prolactinoma or clinically significant hyperprolactinemia** — hexarelin's prolactin elevation could complicate management - **Active anxiety disorder, panic disorder, or acute stress reaction** — HPA axis effects can worsen symptoms **Relative cautions specific to hexarelin:** - Borderline glucose / HbA1c — insulin sensitivity effects appear faster with hexarelin than with cleaner GHS compounds - Mood instability, depression, or insomnia — the HPA axis effects may contribute to worsening - Cardiovascular disease (despite preclinical CD36 data) — the acute blood pressure and cortisol effects are not neutral in this population; clinical cardiac use has not been validated - Concurrent glucocorticoid therapy — pharmacodynamic interference; additive HPA load - Strong family history of colon polyps — baseline colonoscopy before GH-axis intervention - Users who have had previous difficulty tolerating GHS compounds — hexarelin raises ACTH, cortisol and prolactin about as much as GHRP-2 at the same dose (PMID 10195374), and the evidence that ipamorelin spares these hormones comes only from swine (PMID 9849822) **Drug interactions:** - **Glucocorticoids:** Reduced GH response; additive HPA load - **Stimulants (high caffeine, pre-workouts):** Additive sympathomimetic and HPA load - **MAO inhibitors:** Theoretical interaction; specialist oversight - **GLP-1 agonists during weight loss phase:** Opposing appetite signals - **Thyroid hormones:** GH-axis effects can alter thyroid needs - **Exogenous HGH:** Pharmacologically counterproductive **Discontinuation triggers:** - Cortisol elevation >30% above baseline at follow-up labs - ACTH elevation beyond reference range - Prolactin elevation beyond reference range - New or worsened anxiety, insomnia, or mood changes - Fasting glucose persistently >110 mg/dL - Central (abdominal) weight gain beyond caloric intake explanation — suggesting cortisol-driven body composition change - Persistent joint pain or peripheral edema - Worsening sleep apnea - Any cardiovascular symptoms

    Check interactions with the Interaction Checker →

    Additional Notes

    Standard Dosing Reference

    User TierPer InjectionFrequencyCycle Length
    Beginner100 mcg1-2x/day4 weeks on / 4 weeks off
    Intermediate150-200 mcg2x/day4-6 weeks on / 2-4 weeks off
    Advanced200 mcg2-3x/day4-6 weeks on / 2-4 weeks off
    Diagnostic IV1-2 mcg/kgSingle bolus-

    Key Rules for Hexarelin Specifically

    1. Keep cycles short - 4-6 weeks on, not 12+ weeks, due to receptor desensitization
    2. Monitor cortisol and prolactin - essential given its HPA cross-reactivity
    3. Fasted dosing - 2-3 hours after last meal
    4. Subcutaneous route for therapy - IV reserved for diagnostic testing
    5. Single-injection ceiling: ~200 mcg - above this, cortisol rises faster than GH
    6. Do not use continuously for more than 6 weeks

    Concentration and Volume

    Standard 5 mg vial + 2 mL BAC water = 2.5 mg/mL:

    • 100 mcg = 0.04 mL = 4 units on U-100 insulin syringe
    • 150 mcg = 0.06 mL = 6 units
    • 200 mcg = 0.08 mL = 8 units

    Monitoring

    Baseline (essential):

    • IGF-1
    • Fasting insulin, fasting glucose, HbA1c
    • AM cortisol
    • Prolactin
    • Comprehensive metabolic panel

    Week 4 (end of first cycle):

    • IGF-1 (confirm response)
    • Fasting glucose
    • AM cortisol (HPA axis status)
    • Prolactin (if elevated at baseline)

    Week 6 (if extended cycle):

    • Full panel including cortisol, prolactin
    • Consider ACTH if cortisol has risen significantly

    Target IGF-1: Upper quartile of age-adjusted reference range.

    If cortisol has risen >30% above baseline: Discontinue and take a 4-6 week washout before any further GHS use. Consider transitioning to ipamorelin for future GH support.

    When Not to Dose

    • Within 2-3 hours of a meal
    • During acute illness with fever
    • If fasting glucose persistently >110 mg/dL
    • If active HPA axis investigation is underway
    • If current cortisol or prolactin are elevated
    • During periods of significant stress, sleep deprivation, or anxiety exacerbation

    Storage

    • Lyophilized: refrigerated 2-8 deg C, sealed, stable 2 years
    • Reconstituted: refrigerated 2-8 deg C, use within 30 days
    • Never freeze
    • Protect from light

    Frequently Asked Questions

    What is the recommended Hexarelin dosage?

    The typical dose range for Hexarelin is 100–200 mcg per injection. It is usually administered 1–2 times daily; subject to desensitization within 4 weeks. Always start with the lowest effective dose.

    How often should I take Hexarelin?

    1–2 times daily; subject to desensitization within 4 weeks

    Does Hexarelin need to be cycled?

    Yes, typical cycle length is 4-6 weeks (desensitization limits longer use).

    What are Hexarelin side effects?

    ## Common - **Facial flushing and warmth** — More pronounced than other GHRPs. Fades within 15-30 minutes. - **Injection site reactions** — Mild erythema, occasional stinging at SC site. Site rotation minimizes. - **Cortisol elevation** (significant after a 2 mcg/kg IV dose, PMID 7586608; similar with GHRP-2 at the same dose, PMID 10195374) — Transient, peaks 60-90 min post-injection, resolves by 3-4 hours. In healthy users with normal HPA function, typically clinically inconsequential per single dose; cumulative chronic exposure matters more. - **Prolactin elevation** — Usually modest; GHRP-2 at the same intravenous dose raised prolactin to a similar level in young adults ([Arvat et al., 1999](https://pubmed.ncbi.nlm.nih.gov/10195374/)), and no human study has compared hexarelin with ipamorelin. Relevant in users with prolactin-sensitive conditions. - **Appetite stimulation** — Intermediate; noticeable but less pronounced than GHRP-6. - **Vivid dreams** — Common with bedtime dosing. ## Less Common - **Headache** — More frequent than with other GHRPs, particularly in first week. - **Mild nausea** — More common with higher doses or IV administration. - **Transient hypotension** — Primarily with rapid IV bolus; SC route rarely produces meaningful BP changes. - **Fluid retention** — Mild, most pronounced in first 2-3 weeks of daily use. - **Insulin sensitivity reduction** — Measurable with chronic dosing; monitor HbA1c and fasting insulin. - **Paresthesia / scalp tingling** — Transient, benign. ## HPA Axis Effects - **ACTH elevation** — Meaningful and measurable; GHRP-2 at the same intravenous dose raised ACTH to a similar level in young adults ([Arvat et al., 1999](https://pubmed.ncbi.nlm.nih.gov/10195374/)) - **Cumulative cortisol exposure** with chronic daily dosing could theoretically contribute to HPA dysregulation over months - **Patients with anxiety, cortisol-sensitive mood disorders, or adrenal insufficiency are poor candidates** for hexarelin ## Receptor Desensitization - **GH response attenuation** within 4-8 weeks of continuous daily dosing - Dose escalation to overcome attenuation increases cortisol and prolactin exposure disproportionately - Shorter cycling (4-6 weeks on / 2-4 weeks off) is standard for this compound specifically ## Rare but Notable - **Significant hypotension** — primarily with IV; rare with SC - **Hypersensitivity reactions** — rare local or systemic - **Persistent insulin resistance** — with prolonged high-dose use - **HPA axis blunting** — theoretical concern with long-term continuous dosing ## Long-term Theoretical Concerns As with all GH-axis interventions, sustained IGF-1 elevation raises theoretical concerns around chronic mitogenic signaling and cancer risk. Hexarelin's HPA axis effects add an additional concern — chronic low-grade cortisol elevation has independent metabolic consequences (visceral fat accumulation, insulin resistance, immune suppression) that compound over long timescales. Short-cycle use minimizes this risk significantly. ## Signs You Are Overdosing or Need to Stop - Persistent joint pain, peripheral edema, or carpal tunnel symptoms (IGF-1 too high) - Fasting glucose persistently >110 mg/dL - Mood changes, insomnia, or anxiety (HPA axis effects) - Central weight gain or Cushing-like body composition changes - Persistent elevated resting heart rate - Worsening sleep apnea - Any cardiovascular symptoms

    Where can I buy Hexarelin?

    Visit our vendor directory to compare the vendors we track and their Trust Scores.

    Free 2026 Peptide Cheat Sheet (PDF)

    38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.

    Download Free